Inactive Instrument

ALPHANCO VEN

Equities

AVC.P

CA02079V1031

Alphanco Venture Corp. Reports Earnings Results for the Third Quarter Ended April 30, 2019

June 04, 2019 at 08:53 pm

Alphanco Venture Corp. announced earnings results for the third quarter ended April 30, 2019. For the third quarter, the company announced net loss was CAD 80,078. Basic loss per share was CAD 0.02 compared to Basic EPS of CAD 0 a year ago. For the nine months, net loss was CAD 105,890. Basic loss per share was CAD 0.05 compared to Basic EPS of CAD 0 a year ago.

Latest news about ALPHANCO VEN

Alphanco Venture Corp. has Changed its Name to Marvel Biosciences Corp	08/07/21	CI
Marvel Biosciences Corp. Appoints J. Roderick Matheson as Chief Executive Officer	08/07/21	CI
Marvel Biosciences Corp. Appoints Preston J. Maddin as Chief Financial Officer	08/07/21	CI
Marvel Biosciences Corp. Announces Management Appointments	08/07/21	CI
Marvel Biotechnology Inc. completed the acquisition of Alphanco Venture Corp. (TSXV:AVC.P) for CAD 3.8 million in a reverse merger transaction.	13/06/21	CI
Alphanco Venture Corp. Reports Earnings Results for the Third Quarter Ended April 30, 2021	10/06/21	CI
Alphanco Venture Corp. Reports Earnings Results for the Second Quarter Ended January 31, 2021	22/03/21	CI
Marvel Biotechnology Inc. entered into a binding letter agreement to acquire Alphanco Venture Corp. (TSXV:AVC.P) in a reverse merger transaction.	02/11/20	CI
Alphanco Venture Corp. Reports Earnings Results for the Full Year Ended July 31, 2020	16/10/20	CI
Alphanco Venture Corp. Reports Earnings Results for the Third Quarter Ended April 30, 2020	12/05/20	CI
Alphanco Venture Corp. Reports Earnings Results for the Second Quarter Ended January 31, 2020	08/03/20	CI
Alphanco Venture Corp. Reports Earnings Results for the First Quarter Ended October 31, 2019	17/12/19	CI
Alphanco Venture Corp. Reports Earnings Results for the Full Year Ended July 31, 2019	07/11/19	CI
Alphanco Venture Corp. Reports Earnings Results for the Third Quarter Ended April 30, 2019	04/06/19	CI
Alphanco Venture Corp. Reports Earnings Results for the Second Quarter Ended January 31, 2019	25/03/19	CI
Alphanco Venture Corp. has completed an IPO in the amount of CAD 0.4 million.	28/02/19	CI
Alphanco Venture Corp. has filed an IPO in the amount of CAD 0.4 million.	20/12/18	CI
Alphanco Venture Intends To Seek Acquisitions	20/12/18	CI

Chart ALPHANCO VEN

Duration

Period

More charts

Company Profile

Marvel Biosciences Corp, formerly Alphanco Venture Corp, is a Canada-based life sciences company. The Company is focused on discovery and the development of pharmaceutical products for the treatment of neurologically associated diseases (depression and anxiety, Alzheimer's, attention deficit hyperactivity disorder ADHD, and addiction), cancer, and application to the non-neurological disease of non-alcoholic steatohepatitis liver fibrosis. The Company also intends to advance compound 1b (MB-204) into Phase 1 clinical trials for neurological diseases.

Sector

More about the company